Summary

Hypertension is a major public health concern worldwide because of its rising prevalence and concomitant risks of cardiovascular diseases. Coping strategies may encompass a full spectrum of clinical, epidemiological, experimental, and technological factors to inspire front-line practices and shape critical thinking. This entry collection aims to assemble entries of wealthy topics related to clinical, therapeutic, and population sciences of hypertension and cardiovascular diseases that could inform research scientists and healthcare professionals.

Expand All
Entries
Topic Review
Osteopontin in Pulmonary Hypertension
Pulmonary hypertension (PH) is a pathological condition with multifactorial etiology, which is characterized by elevated pulmonary arterial pressure and pulmonary vascular remodeling. Accumulating clinical evidence suggests that circulating osteopontin may serve as a biomarker of PH progression, severity, and prognosis, as well as an indicator of maladaptive right ventricular remodeling and dysfunction. Osteopontin modulates a plethora of cellular processes within the pulmonary vasculature, including cell proliferation, migration, apoptosis, extracellular matrix synthesis, and inflammation via binding to various receptors such as integrins and CD44.
  • 545
  • 18 May 2023
Topic Review
Sudden Cardiac Death in Athletes
The benefits of exercise for cardiovascular and general health are many. However, sudden cardiac death (SCD) may occur in apparently healthy athletes who perform at the highest levels. A diverse spectrum of diseases is implicated in SCD in athletes, and while atherosclerotic coronary artery disease predominates in individuals of >35 years of age, primary cardiomyopathies and ion channelopathies are prevalent in young individuals. Prevention of SCD in athletes relies on the implementation of health policies aimed at the early identification of arrhythmogenic diseases (such as cardiac screening) and successful resuscitation (such as widespread utilization of automatic external defibrillators and training members of the public on cardiopulmonary resuscitation). 
  • 503
  • 17 May 2023
Topic Review
Mechanical Heart Valve Patients with Intracranial Hemorrhage
The management of an intracranial hemorrhage in patients receiving anticoagulant therapy presents a significant challenge for medical professionals. Anticoagulant treatment is intended to prevent blood clotting, but it can worsen active brain bleeds. Despite this risk, avoiding the prothrombotic state caused by mechanical heart valves remains crucial. 
  • 730
  • 17 May 2023
Topic Review
Brain Natriuretic Peptide in Geriatric Heart Failure Evaluation
Heart failure is one of the main morbidity and mortality factors in the general population and especially in elderly patients. Natriuretic peptides, in particular B-type natriuretic peptide (BNP) and its fraction NTproBNP, have gained an increasingly important role in the screening, diagnosis and treatment of heart failure.
  • 514
  • 16 May 2023
Topic Review
Oxidative Stress in Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive disease characterized by elevated artery pressures and pulmonary vascular resistance. Underlying mechanisms comprise endothelial dysfunction, pulmonary artery remodeling and vasoconstriction. Several studies have shown evidence of the critical role of oxidative stress in PH pathophysiology. Alteration of redox homeostasis produces excessive generation of reactive oxygen species, inducing oxidative stress and the subsequent alteration of biological molecules. Exacerbations in oxidative stress production can lead to alterations in nitric oxide signaling pathways, contributing to the proliferation of pulmonary arterial endothelial cells and smooth muscle cells, inducing PH development. 
  • 681
  • 12 May 2023
Topic Review
Types of Senescent Cells in Cardiovascular Diseases
Senescent cell accumulation has been observed in age-associated diseases including cardiovascular diseases. Senescent cells lack proliferative capacity and secrete senescence-associated secretory phenotype (SASP) factors that may cause or worsen many cardiovascular diseases. Therapies targeting senescent cells, especially senolytic drugs that selectively induce senescent cell removal, have been shown to delay, prevent, alleviate, or treat multiple age-associated diseases in preclinical models. 
  • 714
  • 12 May 2023
Topic Review
Therapeutic Implications of Splanchnic Vein Thrombosis
Splanchnic vein thrombosis (SVT) includes portal (portal vein thrombosis, PVT), mesenteric (mesenteric vein thrombosis, MVT) and splenic vein thrombosis, and Budd-Chiari syndrome (BCS). SVT is generally classified as secondary to an identified risk factor or primitive, unprovoked, when causative factors cannot be identified. While much rarer than common venous thromboembolism (VTE), SVT is often challenging to clinicians for both the identification of the causal disorder and for its therapeutic management. The therapeutic approach of SVT is a clinical challenge and considers the manifestations and the site of thrombosis, the risk of SVT progression, recurrence and bleeding. The decision regarding when to start, as well as the type and the duration of anticoagulant therapy is often made empirically.
  • 497
  • 09 May 2023
Topic Review
Cardiovascular Involvement in Tuberculosis
Approximately 60% of patients with tuberculosis (TB) have a cardiovascular disease, the most common associated pathological entities being pericarditis, myocarditis, and coronary artery disease.
  • 911
  • 08 May 2023
Topic Review
Novel Therapeutic Strategies in IHD with Reduced EF
Ischemic heart disease (IHD) continues to be the most common cause of heart failure (HF). Traditional HFrEF therapies, which include beta-blockers, ACE inhibitors (ACEI), angiotensin II receptor blockers (ARB), and mineralocorticoid receptor antagonists (MRA), have extensive data from clinical trials to support their beneficial effect in patients with IHD and HFrEF, translated into improvements in survival and ventricular remodeling and function. The treatment of HF with reduced EF (HFrEF) has been innovated by the introduction of novel pharmacological therapies and device strategies which have been demonstrated to ameliorate the prognosis of HFrEF patients
  • 582
  • 04 May 2023
Topic Review
Coronary Microvascular Dysfunction and Atrial Cardiomyopathy
Ischemia with nonobstructive coronary artery disease (INOCA) is increasingly recognized as a significant cause of angina, myocardial remodeling, and eventually heart failure (HF). Coronary microvascular dysfunction (CMD) is a major endotype of INOCA, and it is caused by structural and functional alterations of the coronary microcirculation. At the same time, atrial cardiomyopathy (ACM) defined by structural, functional, and electrical atrial remodeling has a major clinical impact due to its manifestations: atrial fibrillation (AF), atrial thrombosis, stroke, and HF symptoms. Both these pathologies share similar risk factors and have a high comorbidity burden. CMD causing INOCA and ACM frequently coexist. 
  • 573
  • 04 May 2023
  • Page
  • of
  • 38

Other Entry Collections

>>